(Jan. 30 issue) 1 report the highly anticipated results ... The trial showed a lower risk of the composite primary end point (death from cardiovascular causes or a worsening heart-failure event ...

Table 1 presents the results pertaining to gastrointestinal ... irritation after oral doses of the mercurial. From the Cardiovascular Research Unit, Beth Israel Hospital, the Cardiology Service ...

A new drug slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by ... published in the New England Journal of Medicine, looked at the safety and efficacy ...

The term was first used by a US physician in 1968, who wrote a letter to the highly respected New England Journal of Medicine in which ... in the form of regular table salt (sodium chloride ...

Those decisions have been deferred to future rulemaking. Here are 14 things to know about the final rule: 1. No coverage for GLP-1s: CMS chose not to move forward with the Biden Administration’s ...

How can policy makers and health care leaders ensure affordable, equitable access to GLP-1 medications while managing their ...

TI-CH independently predicted an increased risk of death or recurrence, with an adjusted hazard ratio of 1.80 (95% confidence interval [CI], 1.23 to 2.63) as compared with the absence of CHIP and ...

The placebo-adjusted change in blood pressure was −7.9 mm Hg (97.5% confidence interval [CI], −13.3 to −2.6) in the stable-dose group and −6.5 mm Hg (97.5% CI, −11.8 to −1.2 ...

The values in Table 3.2 of GSTR-3B auto-populates from corresponding inter-state supplies declared in GSTR-1, GSTR-1A, and IFF in requisite tables. It is to inform you that from April-2025 tax ...

Amgen today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial ...